Phase4 Partners
Phase4 Partners is a prominent venture capital firm based in London, specializing in the healthcare sector. Established in 1999, the firm has evolved its investment approach to cater to the needs of major pharmaceutical companies and sophisticated investors globally. With over $400 million invested in 24 companies across Europe and the United States, Phase4 has been instrumental in the development of several groundbreaking products, including Kyprolis and Ultibro Breezhaler. The firm has a notable track record with successful investments such as Pharmion and Arakis, and it continues to support innovative advancements in medicine, including products currently in clinical trials. Phase4 Partners is a member of the British Private Equity and Venture Capital Association and the European Private Equity and Venture Capital Association.
4 past transactions
Avocode
Debt Financing in 2020
Avocode is a software company that develops collaboration tools for designers and developers. Its platform enables teams to import designs from major tools and automatically generate specifications, assets, colors, fonts, and CSS for hand-off. It offers design review, design copywriting, and cloud access to design data via API. The software acts as a bridge between designers and developers, helping to synchronize design and development workflows for web and mobile projects. Founded in 2013 and based in New York, Avocode focuses on streamlining the transition from design to implementation and improving consistency across products.
Avocode
Seed Round in 2016
Avocode is a software company that develops collaboration tools for designers and developers. Its platform enables teams to import designs from major tools and automatically generate specifications, assets, colors, fonts, and CSS for hand-off. It offers design review, design copywriting, and cloud access to design data via API. The software acts as a bridge between designers and developers, helping to synchronize design and development workflows for web and mobile projects. Founded in 2013 and based in New York, Avocode focuses on streamlining the transition from design to implementation and improving consistency across products.
Nabriva Therapeutics
Series B in 2015
Nabriva Therapeutics plc is a biopharmaceutical company focused on developing and commercializing innovative anti-infective agents to address serious infections. The company's lead product candidate, XENLETA, is the first systemic pleuromutilin antibiotic approved by the U.S. Food and Drug Administration for the treatment of community-acquired bacterial pneumonia. In addition to XENLETA, Nabriva is developing CONTEPO, a potential first-in-class epoxide antibiotic aimed at treating complicated urinary tract infections, including acute pyelonephritis. The company is also involved in clinical trials for other indications, including pediatric infections and sexually transmitted infections. Founded in 2005 and headquartered in Dublin, Ireland, Nabriva was previously known as Nabriva Therapeutics Forschungs GmbH before rebranding in 2007.
Nabriva Therapeutics
Venture Round in 2009
Nabriva Therapeutics plc is a biopharmaceutical company focused on developing and commercializing innovative anti-infective agents to address serious infections. The company's lead product candidate, XENLETA, is the first systemic pleuromutilin antibiotic approved by the U.S. Food and Drug Administration for the treatment of community-acquired bacterial pneumonia. In addition to XENLETA, Nabriva is developing CONTEPO, a potential first-in-class epoxide antibiotic aimed at treating complicated urinary tract infections, including acute pyelonephritis. The company is also involved in clinical trials for other indications, including pediatric infections and sexually transmitted infections. Founded in 2005 and headquartered in Dublin, Ireland, Nabriva was previously known as Nabriva Therapeutics Forschungs GmbH before rebranding in 2007.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.